Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases
about
Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs.Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analoguesStructural determinants for the inhibitory ligands of orotidine-5′-monophosphate decarboxylaseNovel Interactions of Fluorinated Nucleotide Derivatives Targeting Orotidine 5′-Monophosphate DecarboxylaseDevelopment of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission TomographyRetrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activationProgressive loss of mitochondrial DNA in thymidine kinase 2-deficient micePotent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine KinaseDesign, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.Characterization of a novel D-lyxose isomerase from Cohnella laevoribosii RI-39 sp. nov.Non-homologous recombination of deoxyribonucleoside kinases from human and Drosophila melanogaster yields human-like enzymes with novel activities.Borononucleotides as substrates/binders for human NMP kinases: enzymatic and spectroscopic evaluation.Mutagenesis of non-conserved active site residues improves the activity and narrows the specificity of human thymidine kinase 2Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs.Nucleic Acid Bioconjugates in Cancer Detection and Therapy.Enantioselectivity of human AMP, dTMP and UMP-CMP kinases.Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue.Polymeric nanogel formulations of nucleoside analogs.Nucleoside analogue delivery systems in cancer therapy.5-Alkynyl-2'-deoxyuridines: chromatography-free synthesis and cytotoxicity evaluation against human breast cancer cellsThymidine kinase and mtDNA depletion in human cardiomyopathy: epigenetic and translational evidence for energy starvation.Deoxyinosine triphosphate induces MLH1/PMS2- and p53-dependent cell growth arrest and DNA instability in mammalian cellsMolecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.Computational molecular biology approaches to ligand-target interactions.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.8-Azapurines as isosteric purine fluorescent probes for nucleic acid and enzymatic research.Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs).Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.Protein phosphatase 2A regulates deoxycytidine kinase activity via Ser-74 dephosphorylation.Purification, activity, and expression levels of two uridine-cytidine kinase isoforms in neuroblastoma cell lines.Retained sensitivity to cytotoxic pyrimidine nucleoside analogs in thymidine kinase 2 deficient human fibroblasts.Nonpolar nucleoside mimics as active substrates for human thymidine kinases.Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors.8-Oxo-7,8-dihydro-2'-deoxyguanosine is not salvaged for DNA synthesis in human leukemic U937 cells.Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation.Structural and energetic properties of the potential HIV-1 reverse transcriptase inhibitors d4A and d4G: a comprehensive theoretical investigation.A thermostable pyrimidine nucleoside phosphorylase from Brevibacillus borstelensis LK01 for synthesizing halogenated nucleosides.cytidine or uridine + ATP => CMP or UMP + ADP [UCK2]Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis.Biosynthesis of nucleoside analogues via thermostable nucleoside phosphorylase.
P2860
Q24540353-456CDAD8-9767-4817-A4CF-017B017ED9FAQ24657596-B209650F-552E-4E30-A646-6505093D1616Q27661430-10A4AD3C-D8CA-47EC-91C9-0FD2CF2F2A86Q27667295-5E640DD1-4B2F-4EAE-8664-25800BB74446Q27679693-0D04F7A6-DBD5-46EC-BA31-F331F4F063B3Q28482505-5D203F37-94AD-4A5A-8F1A-4D5F7ECE88ACQ28513054-E1F0CCBD-AD38-4736-9B30-464207899568Q28550404-7E1313E4-8BB2-486D-A16F-8DBA66F35E55Q30409140-06F90DDE-0D9C-4806-A46D-B0B9B12AB6D2Q33267624-F5A7DF9E-C886-4503-831C-2831C6778835Q33286452-8AF2442B-0D6C-4A25-A843-EF0431064208Q34317110-DD9F55D9-F722-4849-A245-8D2CC939F98FQ35754299-DAEE4590-541B-4865-9172-CF348F47F8CDQ35759090-94F3FD08-65D5-4D9F-B44C-1E8ACBBEAB8AQ35867875-88E30F6B-A48B-4115-B435-5CBD3F67D0ECQ35945458-FA9289D3-8F43-460C-A15C-F76612DF54A7Q36099285-6BEB0857-3EAF-4F08-BC0E-9A3B724D5454Q36668023-4C0E7DEC-208B-46CC-894B-0EB14F0B6632Q36945847-ABE5371F-FA44-4533-AD50-5BC3B29EF80DQ36960377-71C23E1A-CC24-42A8-9B2C-33DF8D472828Q37054681-E5F44175-E996-4545-9DBB-ED4357386247Q37251186-625A6D50-2BF9-4387-A79A-64F54305D772Q37286965-97A1127A-1DA8-4D70-8D35-FA2933CC8A4CQ37684817-8F9ECD8E-C7A5-4737-A029-B0D03F813B2AQ37685527-67AE1FEA-6A3C-4AC8-B0B6-8832C3E81849Q38240046-F5CBDF37-4B22-4A6B-B5DA-309EA186D793Q38243329-D16E8E87-530E-4B84-906E-4CFA303A43D5Q38829114-7A07D11E-43C8-4081-9962-03F186DE112CQ39030818-F5DE59FF-7ABF-4B98-A183-5A6BAAC1D93CQ39139684-2AF87D01-F14B-4EEC-8B01-3150701D4F9FQ39714983-D87320C0-0062-46C5-AD87-4268F6AA0A7EQ39986281-8D2FEC40-670E-452D-A1E7-0CFBA77E374AQ40187481-A17344CC-A5DC-4FDE-9BAD-4B83C08C0BD3Q40301609-D92C81B7-E81B-4E12-B127-E233883711B4Q40595078-D0129FE2-3E9A-4A1A-9B1F-542DB88EC109Q42276579-2C484EDF-4988-46E3-B4FD-EFD19A9CF829Q47717271-DA5538AD-3CF2-4F75-85A9-CD55A7F08435Q50294627-0A2A62CE-B29F-413B-825A-F64426BA3830Q54232437-CD92E245-D62D-4BFA-AE6B-E8C44E34D02BQ54323278-4213D406-9B02-4ADC-9999-57E9EBBFD583
P2860
Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases
description
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im November 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/11/01)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/11/01)
@nl
наукова стаття, опублікована в листопаді 2003
@uk
مقالة علمية (نشرت في نوفمبر 2003)
@ar
name
Substrate specificity and phos ...... ses and ribonucleoside kinases
@ast
Substrate specificity and phos ...... ses and ribonucleoside kinases
@en
Substrate specificity and phos ...... ses and ribonucleoside kinases
@nl
type
label
Substrate specificity and phos ...... ses and ribonucleoside kinases
@ast
Substrate specificity and phos ...... ses and ribonucleoside kinases
@en
Substrate specificity and phos ...... ses and ribonucleoside kinases
@nl
prefLabel
Substrate specificity and phos ...... ses and ribonucleoside kinases
@ast
Substrate specificity and phos ...... ses and ribonucleoside kinases
@en
Substrate specificity and phos ...... ses and ribonucleoside kinases
@nl
P3181
P1476
Substrate specificity and phos ...... ses and ribonucleoside kinases
@en
P2093
An R. Van Rompay
Magnus Johansson
P304
P3181
P356
10.1016/J.PHARMTHERA.2003.07.001
P577
2003-11-01T00:00:00Z